Overview

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

Status:
Completed
Trial end date:
2021-06-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.
Phase:
Phase 2
Details
Lead Sponsor:
Aerogen Pharma Limited
Collaborator:
Ohio State University
Treatments:
Epoprostenol
Tezosentan